Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept.
Publication/Presentation Date
2-25-2024
Abstract
INTRODUCTION: Circulating tumor DNA (ctDNA) is emerging as a promising, non-invasive diagnostic and surveillance biomarker in solid organ malignancy. However, its utility before and after liver transplant (LT) for patients with primary and secondary liver cancers is still underexplored.
METHODS: Patients undergoing LT for hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and colorectal liver metastases (CRLM) with ctDNA testing were included. CtDNA testing was conducted pre-transplant, post-transplant, or both (sequential) from 11/2019 to 09/2023 using Guardant360, Guardant Reveal, and Guardant360 CDx.
RESULTS: 21 patients with HCC (
CONCLUSIONS: Patients with ctDNA positivity experienced recurrence at a higher rate than the ctDNA- patients, indicating the potential role of ctDNA in predicting recurrence after curative-intent transplant. Based on sequential testing, LT has the potential to clear ctDNA, demonstrating the capability of LT in the treatment of systemic disease. Transplant providers should be aware of the potential of donor-derived cell-free DNA and improved approaches are necessary to address such concerns.
Volume
16
Issue
5
ISSN
2072-6694
Published In/Presented At
Hong, H., Wehrle, C. J., Zhang, M., Fares, S., Stitzel, H., Garib, D., Estfan, B., Kamath, S., Krishnamurthi, S., Ma, W. W., Kuzmanovic, T., Azzato, E., Yilmaz, E., Modaresi Esfeh, J., Linganna, M. W., Khalil, M., Pita, A., Schlegel, A., Kim, J., Walsh, R. M., … Aucejo, F. (2024). Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept. Cancers, 16(5), 927. https://doi.org/10.3390/cancers16050927
Disciplines
Medicine and Health Sciences
PubMedID
38473290
Department(s)
Department of Medicine
Document Type
Article